LGN:NASDAQLegence Corp. Analysis
Data as of 2026-04-15 - not real-time
$66.06
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Legence Corp. (LGN) is trading well above its 20‑day (≈$56), 50‑day (≈$53) and 200‑day (≈$45) simple moving averages, signaling strong bullish momentum. The RSI sits near 70, indicating the stock is technically overbought, while the MACD line remains above its signal, reinforcing the bullish bias. However, the market price of $66.06 exceeds the discounted cash‑flow fair value of roughly $47, implying the equity is currently overvalued. Revenue growth of 34.6% is impressive, yet profitability is weak with a negative net margin and operating margin barely above 1%, and the balance sheet is strained by a debt‑to‑equity ratio over 120%. Volatility is elevated (≈58% 30‑day) and beta is high (≈2.5), suggesting the stock will continue to swing sharply.
The sector’s cyclical nature, combined with high leverage and modest cash reserves, heightens financial risk, while the company’s focus on sustainable building systems offers a compelling long‑term narrative. Investors should weigh the strong top‑line growth and technical upside against the overvaluation, thin margins, and heightened market risk before deciding on exposure.
The sector’s cyclical nature, combined with high leverage and modest cash reserves, heightens financial risk, while the company’s focus on sustainable building systems offers a compelling long‑term narrative. Investors should weigh the strong top‑line growth and technical upside against the overvaluation, thin margins, and heightened market risk before deciding on exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators (price above SMAs, MACD bullish)
- RSI approaching overbought territory
- Current overvaluation relative to DCF
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong revenue growth trajectory
- Persistently thin or negative profit margins
- High leverage and elevated beta
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Stock priced well above fair value estimates
- Debt‑heavy balance sheet limiting financial flexibility
- High volatility and cyclical sector exposure
Key Metrics & Analysis
Financial Health
Revenue Growth34.60%
Profit Margin-2.34%
P/E Ratio47.9
ROE-15.58%
ROA2.38%
Debt/Equity121.11
P/B Ratio10.8
Op. Cash Flow$256.9M
Free Cash Flow$228.3M
Industry P/E31.2
Technical Analysis
TrendBullish
RSI69.6
Support$47.80
Resistance$67.10
MA 20$56.20
MA 50$53.34
MA 200$44.58
MACDBullish
VolumeIncreasing
Fear & Greed Index88.64
Valuation
Fair Value$47.17
Target Price$63.05
Upside/Downside-4.55%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.47
Volatility58.48%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.